SGLT2 inhibitors in the real world: too good to be true?

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 9, 2017, Pages 673-675

  Fitchett, David ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG INDICATION; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85028086980     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30259-0     Document Type: Note

References (6)

1. Zinman, B, Wanner, C, Lachin, JM, et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
2. Birkeland, KI, Jorgensen, ME, Carstensen, B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol, 2017 published online Aug 3. http://dx.doi.org/10.1016/S2213-8587(17)30258-9.
3. Kosiborod, M, Cavender, MA, Fu, AZ, et al., on behalf of the CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study. Circulation 136 (2017), 249–259.
4. Neal, B, Perkovic, V, Mahaffey, KW, et al., for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017 published online June 12. DOI:10.1056/NEJMoa1611925.
5. Boyko, EJ, Observational research—opportunities and limitations. J Diabetes Complications 27 (2013), 642–648.
6. Sainani, KL, Propensity scores: uses and limitations. PM&R 4 (2012), 693–697.